Harrow (NASDAQ:HROW) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Harrow (NASDAQ:HROW) in a report issued on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $57.00 target price on the stock.

Separately, B. Riley dropped their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

Harrow Trading Up 0.5 %

Shares of HROW stock opened at $31.04 on Thursday. Harrow has a 52 week low of $9.30 and a 52 week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock’s fifty day moving average is $35.22 and its 200-day moving average is $39.64.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its position in Harrow by 5.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after purchasing an additional 567 shares during the last quarter. Creative Planning grew its position in shares of Harrow by 96.8% in the 2nd quarter. Creative Planning now owns 29,486 shares of the company’s stock valued at $616,000 after acquiring an additional 14,500 shares during the period. SG Americas Securities LLC acquired a new position in shares of Harrow during the 3rd quarter worth about $534,000. Bleakley Financial Group LLC acquired a new position in shares of Harrow during the 3rd quarter worth about $242,000. Finally, Clarus Group Inc. bought a new stake in shares of Harrow in the 3rd quarter valued at about $225,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.